The Latest Breaking News from FDA

Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings growth prospects, the stock has gained more than 260% over the past month because the company submitted an NDA for…

Carl Peters-Bond, from Biopharm Leeches in Hendy, is one of just two FDA registered leech farmers in the world

New COVID-19 boosters targeting today’s most common omicron strains should begin arriving within days

The GOP has understandably cast Anthony Fauci as a villain, but there are few plans to overhaul public health bureaucracies.

Paxlovid goes from COVID game-changer to pandemic enigma

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…